Immix Biopharma (NASDAQ:IMMX) Cut to Sell at Wall Street Zen

Immix Biopharma (NASDAQ:IMMX) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday.

Other equities research analysts have also recently issued reports about the company. Mizuho assumed coverage on Immix Biopharma in a report on Monday. They issued an “outperform” rating and a $14.00 price objective on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immix Biopharma in a research note on Thursday, January 22nd. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $11.00.

Immix Biopharma Trading Down 1.3%

Shares of IMMX stock opened at $7.33 on Friday. Immix Biopharma has a 12-month low of $1.34 and a 12-month high of $7.73. The business’s 50 day moving average is $5.74 and its two-hundred day moving average is $3.87. The company has a market capitalization of $388.20 million, a P/E ratio of -9.52 and a beta of 0.31.

Institutional Trading of Immix Biopharma

Several large investors have recently added to or reduced their stakes in IMMX. Marshall Wace LLP raised its holdings in shares of Immix Biopharma by 3,495.4% during the 4th quarter. Marshall Wace LLP now owns 1,978,743 shares of the company’s stock worth $10,349,000 after acquiring an additional 1,923,708 shares during the period. Bleichroeder LP raised its stake in Immix Biopharma by 17.6% during the fourth quarter. Bleichroeder LP now owns 1,000,000 shares of the company’s stock worth $5,230,000 after purchasing an additional 150,000 shares during the period. Hudson Bay Capital Management LP purchased a new stake in shares of Immix Biopharma in the 4th quarter valued at approximately $176,000. Jane Street Group LLC increased its holdings in shares of Immix Biopharma by 1,016.4% during the 4th quarter. Jane Street Group LLC now owns 167,132 shares of the company’s stock worth $874,000 after buying an additional 152,162 shares during the last quarter. Finally, Tocqueville Asset Management L.P. increased its holdings in shares of Immix Biopharma by 70.3% during the 4th quarter. Tocqueville Asset Management L.P. now owns 68,550 shares of the company’s stock worth $359,000 after buying an additional 28,300 shares during the last quarter. 11.26% of the stock is currently owned by hedge funds and other institutional investors.

About Immix Biopharma

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.